Answers are grounded in this paper and cite their sources.
The liver is a vital organ that performs the majority of the body's metabolic and detoxifying functions. There are various exogenous and endogenous factors that might cause liver issues. Carbon tetrachloride (CCL4) is non-inflammable colorless organic compound and employed in a variety of industrial fields. N-acetylcysteine (NAC) is one of the prospective pharmaceutical candidates possesses multiple clinical applications. The purpose of this study is to determine whether or not NAC has a protective effect in cases of liver injury. Thirty male albino rats were involved in the study, which lasted one month. They were categorized into three groups: control, liver injury group (0.5 ml/kg rat body weight (Bwt) CCL4 administered orally twice a week), and protective group (150 mg/kg Bwt NAC supplied orally). Serum lipid and protein profiles and liver enzymes activities were evaluated. Antioxidant, oxidative stress and anti-inflammatory parameters were also assessed. Additionally, hepatic tissue was subjected to a histopathological investigation. The biochemical and histopathological results revealed dramatic improvement of studied parameters in NAC protective group comparing to liver injury one. Hence, we can conclude that, NAC shown a great potential in attenuating liver injury induced by CCL4 via refinement tumor necrosis factor-alpha, interleukin-6 and reduced glutathione pathway.
No takes yet. Share an insight, caveat, or question.
Mansour et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: